Tyruko Injection
Product Images NDC 61314-543

Product Visual Gallery

This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Tyruko (NDC 61314-543). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sandoz Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure-1 (Fig 1)

A line graph titled 'Time to Increase in Disability Sustained for 12 Weeks in Study MS1' comparing the proportion of patients with sustained increase in disability over time in weeks between placebo and natalizumab treatment groups. The graph shows a lower proportion of disability increase over 120 weeks for natalizumab compared to placebo, with final proportions approximately 17% for natalizumab and 29% for placebo. A p-value of less than 0.001 is noted.*

FDA Label Image

Tyruko-carton (Tyruko 01)

The image shows a carton label for TYRUKO (natalizumab-sztn) injection, 300 mg/15 mL (20 mg/mL) by Sandoz Inc. It is for intravenous infusion, single-dose vial. The label includes storage instructions to refrigerate at 2°C to 8°C (36°F to 46°F) and protect from light, with warnings not to freeze or shake. It also contains inactive ingredients and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.